S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

PhaseBio Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PHAS)

$4.00
-0.04 (-0.99 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$3.96
Now: $4.00
$4.17
50-Day Range
$3.80
MA: $5.09
$8.98
52-Week Range
$2.55
Now: $4.00
$16.65
Volume164,771 shs
Average Volume304,433 shs
Market Capitalization$114.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAS
CUSIPN/A
CIKN/A
Phone610-981-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$670,000.00
Book Value$2.08 per share

Profitability

Net Income$-23,850,000.00
Net Margins-1,447.33%

Miscellaneous

Employees22
Market Cap$114.80 million
Next Earnings Date12/5/2019 (Estimated)
OptionableNot Optionable

Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.


PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. The firm had revenue of $0.70 million for the quarter, compared to analysts' expectations of $0.13 million. PhaseBio Pharmaceuticals had a negative net margin of 1,447.33% and a negative return on equity of 193.85%. View PhaseBio Pharmaceuticals' Earnings History.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, December 5th 2019. View Earnings Estimates for PhaseBio Pharmaceuticals.

What price target have analysts set for PHAS?

6 equities research analysts have issued 12-month price targets for PhaseBio Pharmaceuticals' stock. Their forecasts range from $17.00 to $27.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $20.00 in the next year. This suggests a possible upside of 400.0% from the stock's current price. View Analyst Price Targets for PhaseBio Pharmaceuticals.

What is the consensus analysts' recommendation for PhaseBio Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PhaseBio Pharmaceuticals.

Has PhaseBio Pharmaceuticals been receiving favorable news coverage?

Headlines about PHAS stock have been trending negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PhaseBio Pharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for PhaseBio Pharmaceuticals.

Are investors shorting PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,760,000 shares, an increase of 49.2% from the August 30th total of 1,180,000 shares. Based on an average trading volume of 315,500 shares, the days-to-cover ratio is presently 5.6 days. Approximately 12.7% of the company's stock are sold short. View PhaseBio Pharmaceuticals' Current Options Chain.

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Aurora Cannabis (ACB), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), NIO (NIO), Abeona Therapeutics (ABEO), AcelRx Pharmaceuticals (ACRX), Amarin (AMRN), ArQule (ARQL) and Cara Therapeutics (CARA).

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the folowing people:
  • Mr. Jonathan P. Mow, Pres, CEO & Director (Age 54)
  • Mr. John P. Sharp, Chief Financial Officer (Age 54)
  • Dr. John S. Lee, Chief Medical Officer (Age 51)
  • Mr. Clay Bernardin Thorp, Chairman (Age 51)
  • Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 54)

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $4.00.

How big of a company is PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals has a market capitalization of $114.80 million and generates $670,000.00 in revenue each year. The company earns $-23,850,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. PhaseBio Pharmaceuticals employs 22 workers across the globe.View Additional Information About PhaseBio Pharmaceuticals.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is http://www.phasebio.com/.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]


MarketBeat Community Rating for PhaseBio Pharmaceuticals (NASDAQ PHAS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about PhaseBio Pharmaceuticals and other stocks. Vote "Outperform" if you believe PHAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Featured Article: What is the NASDAQ?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel